Moderna(MRNA) will undertake the first U.S. clinical human trial of potential COVID-19 vaccine
A human clinical trial will begin in Washington on Monday, the trial will test the effects of an experimental vaccine shot developed by the National Institutes of Health and drugmaker Moderna. They are using a gene-based method that uses messenger RNA to trigger an immune response in the target individual, unlike most vaccines that have active or inactive samples of the virus. Moderna is a young company built around this gene-based approach to drug therapy development. They were set to begin testing in April, but due to the spread of COVID-19, they will begin testing sooner. Moderna is not the only company creating a vaccine to fight COVID-19, there are both public and private companies, that have been racing to the cure.
What makes Moderna different? They are fast-tracking the human trial aspect of the clinical testing program. Since the vaccine is gene-based some of the participants will not run the risk of contracting the virus during testing. There are a lot of unknowns when it comes to injecting a new drug into a young and healthy person. The vaccine being tested will have to prove efficiency and safety on the reported 45 individuals taking part in this program.
March 16, 2020